Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.

Literature DB >> 16731957

Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.

Vincent Holl¹, Maryse Peressin, Thomas Decoville, Sylvie Schmidt, Susan Zolla-Pazner, Anne-Marie Aubertin, Christiane Moog.

Abstract

Only five monoclonal antibodies (MAbs) neutralizing a broad range of primary isolates (PI) have been identified up to now. We have found that some MAbs with no neutralizing activities according to the "conventional" neutralization assay, involving phytohemagglutinin-stimulated peripheral blood mononuclear cells as targets, efficiently inhibit the replication of human immunodeficiency virus type 1 (HIV-1) PI in macrophages and immature dendritic cells (iDC). The mechanism of inhibition is distinct from the neutralization of infectivity occurring via Fab fragments and involves the interaction of the F portion with the FcgammaRs present on macrophages and iDC. We propose that, if such nonneutralizing inhibitory antibodies limit mucosal HIV transmission, they should be induced by vaccination.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2006 PMID： 16731957 PMCID： PMC1472578 DOI： 10.1128/JVI.02625-05

Source DB: PubMed Journal: J Virol ISSN： 0022-538X Impact factor: 5.103

17 in total

1. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.

Authors: Thomas J Ketas; Per Johan Klasse; Catherine Spenlehauer; Mirjana Nesin; Ines Frank; Melissa Pope; Julie M Strizki; Gregory R Reyes; Bahige M Baroudy; John P Moore
Journal: AIDS Res Hum Retroviruses Date: 2003-03 Impact factor: 2.205

2. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors: J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal: Nat Med Date: 2000-02 Impact factor: 53.440

Review 3. Neutralizing antibodies against HIV -- back in the major leagues?

Authors: Flavia Ferrantelli; Ruth M Ruprecht
Journal: Curr Opin Immunol Date: 2002-08 Impact factor: 7.486

4. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.

Authors: C E Hioe; S Xu; P Chigurupati; S Burda; C Williams; M K Gorny; S Zolla-Pazner
Journal: Int Immunol Date: 1997-09 Impact factor: 4.823

5. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.

Authors: J P Moore; Y Cao; D D Ho; R A Koup
Journal: J Virol Date: 1994-08 Impact factor: 5.103

6. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.

Authors: J Y Xu; M K Gorny; T Palker; S Karwowska; S Zolla-Pazner
Journal: J Virol Date: 1991-09 Impact factor: 5.103

7. Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.

Authors: P N Nyambi; A Nádas; H A Mbah; S Burda; C Williams; M K Gorny; S Zolla-Pazner
Journal: J Virol Date: 2000-11 Impact factor: 5.103

Review 8. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir.

Authors: Stefano Aquaro; Raffaele Caliò; Jan Balzarini; Maria Concetta Bellocchi; Enrico Garaci; Carlo Federico Perno
Journal: Antiviral Res Date: 2002-08 Impact factor: 5.970

9. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors: C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal: J Virol Date: 1997-05 Impact factor: 5.103

10. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.

Authors: Yoshiaki Nishimura; Tatsuhiko Igarashi; Nancy L Haigwood; Reza Sadjadpour; Olivia K Donau; Charles Buckler; Ron J Plishka; Alicia Buckler-White; Malcolm A Martin
Journal: Proc Natl Acad Sci U S A Date: 2003-11-19 Impact factor: 11.205

75 in total

Review 1. Strategies for eliciting HIV-1 inhibitory antibodies.

Authors: Georgia D Tomaras; Barton F Haynes
Journal: Curr Opin HIV AIDS Date: 2010-09 Impact factor: 4.283

2. HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation.

Authors: Thijs van Montfort; Dirk Eggink; Maikel Boot; Michael Tuen; Catarina E Hioe; Ben Berkhout; Rogier W Sanders
Journal: J Immunol Date: 2011-09-28 Impact factor: 5.422

3. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors: Thorsten Demberg; Ruth H Florese; Megan J Heath; Kay Larsen; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; David Venzon; Richard Grant; L Jean Patterson; Birgit Korioth-Schmitz; Adam Buzby; Dilani Dombagoda; David C Montefiori; Norman L Letvin; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal: J Virol Date: 2007-01-17 Impact factor: 5.103

4. Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors: David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal: Curr Opin HIV AIDS Date: 2007-05 Impact factor: 4.283

5. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees.

Authors: Pinghuang Liu; Nicole L Yates; Xiaoying Shen; Mattia Bonsignori; M Anthony Moody; Hua-Xin Liao; Youyi Fong; S Munir Alam; R Glenn Overman; Thomas Denny; Guido Ferrari; Christina Ochsenbauer; John C Kappes; Victoria R Polonis; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; David C Montefiori; Peter Gilbert; Nelson L Michael; Jerome H Kim; Barton F Haynes; Georgia D Tomaras
Journal: J Virol Date: 2013-05-08 Impact factor: 5.103

6. A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model.

Authors: Rohan Keshwara; Katie R Hagen; Tiago Abreu-Mota; Amy B Papaneri; David Liu; Christoph Wirblich; Reed F Johnson; Matthias J Schnell
Journal: J Virol Date: 2019-03-05 Impact factor: 5.103

7. Stimulation of HIV-1 replication in immature dendritic cells in contact with primary CD4 T or B lymphocytes.

Authors: Vincent Holl; Ke Xu; Maryse Peressin; Alexandre Lederle; Marina Elizabeth Biedma; Maryse Delaporte; Thomas Decoville; Sylvie Schmidt; Géraldine Laumond; Anne-Marie Aubertin; Christiane Moog
Journal: J Virol Date: 2010-02-10 Impact factor: 5.103